{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T03:19:58Z","timestamp":1790133598954,"version":"4.0.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,9,30]],"date-time":"2016-09-30T00:00:00Z","timestamp":1475193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,9,30]],"date-time":"2016-09-30T00:00:00Z","timestamp":1475193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Microtubule-associated protein 7 (<jats:italic>MAP7<\/jats:italic>) plays an important role in cancer cells. In this study, we identified the prognostic significance of <jats:italic>MAP7<\/jats:italic> expression in cytogenetically normal acute myeloid leukemia (CN-AML) patients (aged &lt;60 years) based on several microarray datasets. In the first group (n\u2009=\u2009129), high <jats:italic>MAP7<\/jats:italic> expression (<jats:italic>MAP7<\/jats:italic><jats:sup>high<\/jats:sup>) was associated with adverse overall survival (OS; <jats:italic>P<\/jats:italic>\u2009=\u20090.0441) and event-free survival (EFS; <jats:italic>P<\/jats:italic>\u2009=\u20090.0114) compared with low <jats:italic>MAP7<\/jats:italic> expression (<jats:italic>MAP7<\/jats:italic><jats:sup>low<\/jats:sup>). In addition, the prognostic significance of <jats:italic>MAP7<\/jats:italic> was confirmed by European Leukemia Net (ELN) intermediate-I genetic categories and multivariable analysis. In the second independent group of CN-AML patients (aged &lt;60 years), <jats:italic>MAP7<\/jats:italic><jats:sup>high<\/jats:sup> was also associated with adverse OS (n\u2009=\u200988, OS; <jats:italic>P<\/jats:italic>\u2009=\u20090.00811). To understand the inherent mechanisms of <jats:italic>MAP7<\/jats:italic>\u2019s prognosis, we investigated genome-wide gene\/microRNA expression signatures associated with <jats:italic>MAP7<\/jats:italic> expression. Several known oncogenic genes\/microRNAs and anti-oncogenic genes\/microRNAs were disordered in <jats:italic>MAP7<\/jats:italic><jats:sup>high<\/jats:sup> CN-AML patients. In conclusion, <jats:italic>MAP7<\/jats:italic><jats:sup>high<\/jats:sup> is an adverse prognostic biomarker for CN-AML, which may be attributed to the distinctive genome-wide gene\/microRNA expression and related cell signaling pathways.<\/jats:p>","DOI":"10.1038\/srep34546","type":"journal-article","created":{"date-parts":[[2016,9,30]],"date-time":"2016-09-30T09:22:27Z","timestamp":1475227347000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["High expression of MAP7 predicts adverse prognosis in young patients with cytogenetically normal acute myeloid leukemia"],"prefix":"10.1038","volume":"6","author":[{"given":"Lin","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaping","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keman","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenrong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,30]]},"reference":[{"key":"BFsrep34546_CR1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0268-960X(03)00040-7","volume":"18","author":"K Mrozek","year":"2004","unstructured":"Mrozek, K., Heerema, N. A. & Bloomfield, C. D. Cytogenetics in acute leukemia. Blood Rev 18, 115\u2013136 (2004).","journal-title":"Blood Rev"},{"key":"BFsrep34546_CR2","doi-asserted-by":"crossref","first-page":"5660","DOI":"10.1182\/blood-2010-06-290536","volume":"116","author":"S Schwind","year":"2010","unstructured":"Schwind, S. et al. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 116, 5660\u20135669 (2010).","journal-title":"Blood"},{"key":"BFsrep34546_CR3","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/leu.2014.267","volume":"29","author":"C Niederwieser","year":"2015","unstructured":"Niederwieser, C. et al. Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. Leukemia 29, 567\u2013575 (2015).","journal-title":"Leukemia"},{"key":"BFsrep34546_CR4","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.18632\/oncotarget.3024","volume":"6","author":"JL Shi","year":"2015","unstructured":"Shi, J. L., Fu, L. & Wang, W. D. High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia. Oncotarget 6, 5299\u20135309 (2015).","journal-title":"Oncotarget"},{"key":"BFsrep34546_CR5","doi-asserted-by":"crossref","first-page":"8144","DOI":"10.18632\/oncotarget.3519","volume":"6","author":"L Fu","year":"2015","unstructured":"Fu, L. et al. Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia. Oncotarget 6, 8144\u20138154 (2015).","journal-title":"Oncotarget"},{"key":"BFsrep34546_CR6","doi-asserted-by":"crossref","unstructured":"Shi, J. L. et al. Overexpression of ATP1B1 predicts an adverse prognosis in cytogenetically normal acute myeloid leukemia. Oncotarget (2015).","DOI":"10.18632\/oncotarget.6226"},{"key":"BFsrep34546_CR7","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1182\/blood-2012-02-411827","volume":"120","author":"KH Metzeler","year":"2012","unstructured":"Metzeler, K. H. et al. High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia. Blood 120, 2118\u20132126 (2012).","journal-title":"Blood"},{"key":"BFsrep34546_CR8","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1200\/JCO.2012.44.3184","volume":"31","author":"Z Li","year":"2013","unstructured":"Li, Z. et al. Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. J Clin Oncol 31, 1172\u20131181 (2013).","journal-title":"J Clin Oncol"},{"key":"BFsrep34546_CR9","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1158\/1078-0432.CCR-06-3040","volume":"13","author":"KM Bhat","year":"2007","unstructured":"Bhat, K. M. & Setaluri, V. Microtubule-associated proteins as targets in cancer chemotherapy. Clin Cancer Res 13, 2849\u20132854 (2007).","journal-title":"Clin Cancer Res"},{"key":"BFsrep34546_CR10","first-page":"579","volume":"33","author":"C Blum","year":"2008","unstructured":"Blum, C. et al. The expression ratio of Map7\/B2M is prognostic for survival in patients with stage II colon cancer. Int J Oncol 33, 579\u2013584 (2008).","journal-title":"Int J Oncol"},{"key":"BFsrep34546_CR11","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3324\/haematol.2011.057067","volume":"98","author":"N Omidvar","year":"2013","unstructured":"Omidvar, N. et al. PML-RARalpha co-operates with Sox4 in acute myeloid leukemia development in mice. Haematologica 98, 424\u2013427 (2013).","journal-title":"Haematologica"},{"key":"BFsrep34546_CR12","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc2826","volume":"10","author":"N Shah","year":"2010","unstructured":"Shah, N. & Sukumar, S. The Hox genes and their roles in oncogenesis. Nat Rev Cancer 10, 361\u2013371 (2010).","journal-title":"Nat Rev Cancer"},{"key":"BFsrep34546_CR13","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1182\/blood.V98.12.3413","volume":"98","author":"E Satterwhite","year":"2001","unstructured":"Satterwhite, E. et al. The BCL11 gene family: involvement of BCL11A in lymphoid malignancies. Blood 98, 3413\u20133420 (2001).","journal-title":"Blood"},{"key":"BFsrep34546_CR14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ccell.2015.07.017","volume":"28","author":"TD Somerville","year":"2015","unstructured":"Somerville, T. D. et al. Frequent Derepression of the Mesenchymal Transcription Factor Gene FOXC1 in Acute Myeloid Leukemia. Cancer Cell 28, 329\u2013342 (2015).","journal-title":"Cancer Cell"},{"key":"BFsrep34546_CR15","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1172\/JCI68557","volume":"123","author":"S Goyama","year":"2013","unstructured":"Goyama, S. et al. Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. J Clin Invest 123, 3876\u20133888 (2013).","journal-title":"J Clin Invest"},{"key":"BFsrep34546_CR16","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3324\/haematol.2015.124032","volume":"100","author":"MP Garcia-Cuellar","year":"2015","unstructured":"Garcia-Cuellar, M. P., Steger, J., Fuller, E., Hetzner, K. & Slany, R. K. Pbx3 and Meis1 cooperate through multiple mechanisms to support Hox-induced murine leukemia. Haematologica 100, 905\u2013913 (2015).","journal-title":"Haematologica"},{"key":"BFsrep34546_CR17","doi-asserted-by":"crossref","unstructured":"Fu, L. et al. High expression of RUNX1 is associated with poorer outcomes in cytogenetically normal acute myeloid leukemia. Oncotarget (2016).","DOI":"10.18632\/oncotarget.7489"},{"key":"BFsrep34546_CR18","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.3109\/10428194.2014.893305","volume":"55","author":"GS Laszlo","year":"2014","unstructured":"Laszlo, G. S. et al. High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children\u2019s Oncology Group. Leuk Lymphoma 55, 2817\u20132821 (2014).","journal-title":"Leuk Lymphoma"},{"key":"BFsrep34546_CR19","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood-2011-12-397083","volume":"120","author":"M Luesink","year":"2012","unstructured":"Luesink, M. et al. High GATA2 expression is a poor prognostic marker in pediatric acute myeloid leukemia. Blood 120, 2064\u20132075 (2012).","journal-title":"Blood"},{"key":"BFsrep34546_CR20","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1182\/blood-2011-04-346767","volume":"118","author":"RJ Byers","year":"2011","unstructured":"Byers, R. J., Currie, T., Tholouli, E., Rodig, S. J. & Kutok, J. L. MSI2 protein expression predicts unfavorable outcome in acute myeloid leukemia. Blood 118, 2857\u20132867 (2011).","journal-title":"Blood"},{"key":"BFsrep34546_CR21","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.leukres.2011.08.006","volume":"35","author":"A Kuhnl","year":"2011","unstructured":"Kuhnl, A. et al. High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia. Leuk Res 35, 1585\u20131590 (2011).","journal-title":"Leuk Res"},{"key":"BFsrep34546_CR22","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.leukres.2015.10.014","volume":"40","author":"G Montano","year":"2016","unstructured":"Montano, G. et al. The hematopoietic tumor suppressor interferon regulatory factor 8 (IRF8) is upregulated by the antimetabolite cytarabine in leukemic cells involving the zinc finger protein ZNF224, acting as a cofactor of the Wilms\u2019 tumor gene 1 (WT1) protein. Leuk Res 40, 60\u201367 (2016).","journal-title":"Leuk Res"},{"key":"BFsrep34546_CR23","doi-asserted-by":"crossref","first-page":"16229","DOI":"10.1038\/srep16229","volume":"5","author":"MT Chen","year":"2015","unstructured":"Chen, M. T. et al. ZFP36L1 promotes monocyte\/macrophage differentiation by repressing CDK6. Sci Rep 5, 16229 (2015).","journal-title":"Sci Rep"},{"key":"BFsrep34546_CR24","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/ncomms1681","volume":"3","author":"Z Li","year":"2012","unstructured":"Li, Z. et al. miR-196b directly targets both HOXA9\/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. Nat Commun 3, 688 (2012).","journal-title":"Nat Commun"},{"key":"BFsrep34546_CR25","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4274\/Tjh.2012.0171","volume":"30","author":"M Sharifi","year":"2013","unstructured":"Sharifi, M., Salehi, R., Gheisari, Y. & Kazemi, M. Inhibition of MicroRNA miR-92a Inhibits Cell Proliferation in Human Acute Promyelocytic Leukemia. Turk J Haematol 30, 157\u2013162 (2013).","journal-title":"Turk J Haematol"},{"key":"BFsrep34546_CR26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/1475-2867-13-110","volume":"13","author":"L Zhang","year":"2013","unstructured":"Zhang, L. et al. MiR-99a may serve as a potential oncogene in pediatric myeloid leukemia. Cancer Cell Int 13, 110 (2013).","journal-title":"Cancer Cell Int"},{"key":"BFsrep34546_CR27","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s12185-015-1829-6","volume":"102","author":"Y Zhi","year":"2015","unstructured":"Zhi, Y. et al. Serum level of miR-10-5p as a prognostic biomarker for acute myeloid leukemia. Int J Hematol 102, 296\u2013303 (2015).","journal-title":"Int J Hematol"},{"key":"BFsrep34546_CR28","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.leukres.2015.08.009","volume":"39","author":"L Koutova","year":"2015","unstructured":"Koutova, L. et al. The impact of standard chemotherapy on miRNA signature in plasma in AML patients. Leuk Res 39, 1389\u20131395 (2015).","journal-title":"Leuk Res"},{"key":"BFsrep34546_CR29","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa074256","volume":"358","author":"G Marcucci","year":"2008","unstructured":"Marcucci, G. et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 358, 1919\u20131928 (2008).","journal-title":"N Engl J Med"},{"key":"BFsrep34546_CR30","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1038\/onc.2011.62","volume":"30","author":"XN Gao","year":"2011","unstructured":"Gao, X. N. et al. MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia. Oncogene 30, 3416\u20133428 (2011).","journal-title":"Oncogene"},{"key":"BFsrep34546_CR31","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/cgt.2014.44","volume":"21","author":"Z Xishan","year":"2014","unstructured":"Xishan, Z., Xianjun, L., Ziying, L., Guangxin, C. & Gang, L. The malignancy suppression role of miR-23a by targeting the BCR\/ABL oncogene in chromic myeloid leukemia. Cancer Gene Ther 21, 397\u2013404 (2014).","journal-title":"Cancer Gene Ther"},{"key":"BFsrep34546_CR32","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1111\/febs.12926","volume":"281","author":"HM Ahmad","year":"2014","unstructured":"Ahmad, H. M. et al. miR-22 regulates expression of oncogenic neuro-epithelial transforming gene 1, NET1. FEBS J 281, 3904\u20133919 (2014).","journal-title":"FEBS J"},{"key":"BFsrep34546_CR33","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/ijc.28043","volume":"133","author":"S Babashah","year":"2013","unstructured":"Babashah, S. et al. Targeting of the signal transducer Smo links microRNA-326 to the oncogenic Hedgehog pathway in CD34+ CML stem\/progenitor cells. Int J Cancer 133, 579\u2013589 (2013).","journal-title":"Int J Cancer"},{"key":"BFsrep34546_CR34","doi-asserted-by":"crossref","first-page":"19102","DOI":"10.18632\/oncotarget.3905","volume":"6","author":"BoM Dal","year":"2015","unstructured":"Dal, Bo M. et al. The SIRT1\/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells. Oncotarget 6, 19102\u201319117 (2015).","journal-title":"Oncotarget"},{"key":"BFsrep34546_CR35","doi-asserted-by":"crossref","unstructured":"Bian, X. et al. Down-expression of miR-152 lead to impaired anti-tumor effect of NK via upregulation of HLA-G. Tumour Biol (2015).","DOI":"10.1007\/s13277-015-3669-7"},{"key":"BFsrep34546_CR36","doi-asserted-by":"crossref","first-page":"949","DOI":"10.4149\/neo_2015_115","volume":"62","author":"D Jurkovicova","year":"2015","unstructured":"Jurkovicova, D. et al. microRNA expression profiling as supportive diagnostic and therapy prediction tool in chronic myeloid leukemia. Neoplasma 62, 949\u2013958 (2015).","journal-title":"Neoplasma"},{"key":"BFsrep34546_CR37","doi-asserted-by":"crossref","first-page":"e1564","DOI":"10.1038\/cddis.2014.507","volume":"5","author":"O Fortunato","year":"2014","unstructured":"Fortunato, O. et al. Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction. Cell Death Dis 5, e1564 (2014).","journal-title":"Cell Death Dis"},{"key":"BFsrep34546_CR38","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1038\/bjc.2013.243","volume":"108","author":"A Vislovukh","year":"2013","unstructured":"Vislovukh, A. et al. Proto-oncogenic isoform A2 of eukaryotic translation elongation factor eEF1 is a target of miR-663 and miR-744. Br J Cancer 108, 2304\u20132311 (2013).","journal-title":"Br J Cancer"},{"key":"BFsrep34546_CR39","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1158\/1535-7163.MCT-14-0243","volume":"13","author":"H Tang","year":"2014","unstructured":"Tang, H. et al. miR-185 suppresses tumor proliferation by directly targeting E2F6 and DNMT1 and indirectly upregulating BRCA1 in triple-negative breast cancer. Mol Cancer Ther 13, 3185\u20133197 (2014).","journal-title":"Mol Cancer Ther"},{"key":"BFsrep34546_CR40","doi-asserted-by":"crossref","first-page":"34968","DOI":"10.18632\/oncotarget.5198","volume":"6","author":"C Song","year":"2015","unstructured":"Song, C. et al. miR-200c inhibits breast cancer proliferation by targeting KRAS. Oncotarget 6, 34968\u201334978 (2015).","journal-title":"Oncotarget"},{"key":"BFsrep34546_CR41","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.bbrc.2015.03.088","volume":"460","author":"X Li","year":"2015","unstructured":"Li, X. et al. miR-340 inhibits glioblastoma cell proliferation by suppressing CDK6, cyclin-D1 and cyclin-D2. Biochem Biophys Res Commun 460, 670\u2013677 (2015).","journal-title":"Biochem Biophys Res Commun"},{"key":"BFsrep34546_CR42","doi-asserted-by":"crossref","first-page":"e50895","DOI":"10.1371\/journal.pone.0050895","volume":"7","author":"KA Scheibner","year":"2012","unstructured":"Scheibner, K. A. et al. MiR-27a functions as a tumor suppressor in acute leukemia by regulating 14-3-3theta. PLoS One 7, e50895 (2012).","journal-title":"PLoS One"},{"key":"BFsrep34546_CR43","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000186051","volume":"9","author":"KH Lee","year":"2009","unstructured":"Lee, K. H. et al. Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. Pancreatology 9, 293\u2013301 (2009).","journal-title":"Pancreatology"},{"key":"BFsrep34546_CR44","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.18632\/oncotarget.717","volume":"3","author":"V Siragam","year":"2012","unstructured":"Siragam, V. et al. MicroRNA miR-98 inhibits tumor angiogenesis and invasion by targeting activin receptor-like kinase-4 and matrix metalloproteinase-11. Oncotarget 3, 1370\u20131385 (2012).","journal-title":"Oncotarget"},{"key":"BFsrep34546_CR45","doi-asserted-by":"crossref","unstructured":"Chiu, Y. C. et al. Prognostic significance of NPM1 mutation-modulated microRNA-mRNA regulation in acute myeloid leukemia. Leukemia (2015).","DOI":"10.1038\/leu.2015.253"},{"key":"BFsrep34546_CR46","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1600-0609.2009.01389.x","volume":"84","author":"A Potapova","year":"2010","unstructured":"Potapova, A. et al. Epigenetic inactivation of tumour suppressor gene KLF11 in myelodysplastic syndromes*. Eur J Haematol 84, 298\u2013303 (2010).","journal-title":"Eur J Haematol"},{"key":"BFsrep34546_CR47","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1136\/jmg.2005.035253","volume":"43","author":"E Rudd","year":"2006","unstructured":"Rudd, E. et al. Spectrum and clinical implications of syntaxin 11 gene mutations in familial haemophagocytic lymphohistiocytosis: association with disease-free remissions and haematopoietic malignancies. J Med Genet 43, e14 (2006).","journal-title":"J Med Genet"},{"key":"BFsrep34546_CR48","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.297.5588.1807d","volume":"297","author":"M Esteller","year":"2002","unstructured":"Esteller, M. et al. Cancer epigenetics and methylation. Science 297, 1807\u20131808; discussion 1807-1808 (2002).","journal-title":"Science"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep34546","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep34546.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep34546.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T21:51:31Z","timestamp":1672869091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep34546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,30]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,14]]}},"alternative-id":["BFsrep34546"],"URL":"https:\/\/doi.org\/10.1038\/srep34546","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,30]]},"assertion":[{"value":"20 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34546"}}